DOMH

Business Context and Reporting Period

Company: Spherix Incorporated (Note: Input metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as Spherix Incorporated).

Reporting Period: Fiscal year ended December 31, 2004.

Business Overview: The Company operates two primary divisions: BioSpherix, a biotechnology R&D arm focused on the proprietary sweetener tagatose (and its non-food brand Naturlose), and InfoSpherix, an information services provider offering contact center and reservation services primarily to government agencies. InfoSpherix generated 99% of total revenue in 2004.

Key Financial Metrics

Segment Performance: InfoSpherix revenue was $22.2 million (99% of total), while BioSpherix revenue was $127,000 (less than 1%). BioSpherix contributed a $794,000 operating loss in 2004.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 24% ($4.3 million) driven by InfoSpherix, which added five new government contracts and acquired six reservation contracts from Daksoft, Inc. in March 2004.
• BioSpherix Revenue Decline: BioSpherix revenue decreased by approximately $900,000 compared to 2003. This was primarily due to the recognition of a $1 million arbitration settlement payment from Arla Foods in 2003, which did not recur in 2004.
• Increased Operating Costs: Direct contract and operating costs rose 42% ($5.1 million) due to new contracts and overhead from expanded facilities in Cumberland, MD, Rapid City, SD, and Annapolis, MD.
• Legal Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 14% ($885,000), largely due to a $1.5 million drop in legal fees following the 2003 settlement of the Arla arbitration.
• Wider Net Loss: Net loss increased by $565,000 to $2.8 million, driven by higher operating costs in InfoSpherix and the absence of the one-time 2003 settlement revenue in BioSpherix.

Guidance, Outlook, and Risks

• Outlook: InfoSpherix sales backlog reached a record $61 million (up from $28.6 million in 2003). The Company expects capital needs for 2005 to be lower than 2004. Management anticipates the South Dakota contact center will break even in 2005 before operations are relocated to Maryland.
• BioSpherix Strategy: Future royalties depend on Arla Foods' ability to increase tagatose sales and potentially build a larger manufacturing plant (estimated 18-24 months). Spherix is actively marketing Naturlose for non-food uses (e.g., pharmaceuticals, toothpaste) and has secured its first pharmaceutical sale.
• Government Contract Risks: The Company is heavily reliant on government contracts (U.S. Government, State of Maryland, State of Michigan each account for >10% of revenue). The National Park Service (NPS) contract was extended through September 2005, but the combined NPS/Forest Service procurement was reopened after a successful protest by Spherix; the outcome of the rebid is pending.
• Liquidity: The Company has a $2 million line of credit with Bank of America, with $1.97 million outstanding and only $33,000 available. The line expires June 30, 2005, and renewal is anticipated but not guaranteed.
• Regulatory Costs: Implementation of Sarbanes-Oxley Section 404 is expected to incur significant costs over the next two years.

Investor Verification Checklist

• Contract Renewals: Verify the status of the rebid for the combined National Park Service and Forest Service reservation contract.
• Debt Renewal: Confirm the renewal of the $2 million line of credit expiring June 30, 2005, given the low remaining availability.
• BioSpherix Royalties: Monitor Arla Foods' decision on constructing a larger tagatose plant, as current royalties are minimal due to limited production capacity.
• Customer Concentration: Assess the risk associated with the top three customers (U.S. Gov, MD, MI) representing a significant portion of revenue.
• Operating Efficiency: Track the performance of the Rapid City, SD facility to ensure it meets the break-even target for 2005.